For example, SRD5A3 is overexpressed in hepatocellular carcinoma, breast carcinoma, endometrial carcinoma, and prostate carcinoma, and patients with SRD5A3 high expression suggest a poor prognosis [19–21]. Here, SRD5A3 is linked to breast carcinoma.